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under the Community Drugs Scheme. Of these, 2 treatments were reimbursed after a price 
reduction, 2 were borderline, and 1 treatment was cost-effective under the General Medical 
Services scheme but not the Drugs Payment Scheme. Of the 11 products reimbursed by 
NCPE, 5 were recommended by NICE (45%), 6 by SMC (55%) and 1 by AWMSG (9%). 
Not all of the 11 treatments were reviewed by NICE, SMC and/or AWMSG. Furthermore, 
2 of the 11 treatments have been withdrawn in Scotland, England and Wales. Limited 
clinical/economic data was the reason for the one non-recommendation by the SMC. a 
more detailed analysis will be presented. CONCLUSIONS: Although requirements for 
HTA submissions vary between countries, demonstrating cost-effectiveness is a key factor 
for reimbursement in all markets investigated.
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REFINING INPATIENT PSYCHIATRIC FACILITY REIMBURSEMENT: 
LESSONS FROM OTHER MEDICARE PROSPECTIVE PAYMENT SYSTEMS
Pierce CA, Jones NA, Brocketti JJ
The Resource Group, Richﬁ eld, OH, USA
OBJECTIVES: The Inpatient Psychiatric Facility Prospective Payment System (IPF 
PPS) is the youngest of the Medicare PPSs. Inpatient Psychiatric Facilities (IPFs) were 
excluded from the acute care inpatient diagnosis-related groups (DRG) system as it 
was thought to be a poor predictor of resource use for psychiatric patients. Although 
the IPF PPS was to include a patient classiﬁ cation system to reﬂ ect the differences in 
resource use and costs among IPFs, it was implemented without an associated assess-
ment tool. This project reviews Medicare PPSs in which diagnosis is not an adequate 
predictor of resource use; compares data collected via the related assessment instru-
ments, and discusses applicability to the IPF PPS. METHODS: The Medicare prospec-
tive payment systems were evaluated and the relevant systems isolated. The systems’ 
deﬁ ning criteria were deﬁ ned and the related assessment instruments explored for 
identifying measures. RESULTS: Under the current IPF PPS, Medicare pays for the 
per diem costs associated with furnishing covered inpatient psychiatric services via a 
nationally established base rate adjusted by geographic, facility and patient factors. 
Patient characteristics are limited to seventeen Medicare severity-diagnosis related 
groups (MS-DRGs), age, length of stay and certain co-morbidities but, unlike home 
health, skilled nursing and rehabilitation facility systems, do not account for functional 
status or other contributors to resource consumption. CONCLUSIONS: Patients in 
IPFs may vary in care needs despite common MS-DRG classiﬁ cation, thus require 
different resources. With limited ability to adjust beyond primary diagnosis, the 
current IPF PPS may misalign facility payment and expenses, ultimately impacting 
access to care. By analyzing other Medicare PPSs policy makers may positively con-
tribute to the reﬁ nement of this newest system.
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OBJECTIVES: The therapeutic reference price (RP) system in Germany is regarded as 
a successful mechanism to reduce pharmaceutical spending. However, later introduced 
price directed measures such as the so-called payer contracts (pharmaceutical tender 
contracts (TC) interact with the reference price mechanism. The aim of this paper is to 
compare and analyze the effects of both instruments on pharmaceutical price, volume 
and expenditure for substances at the period around loss of exclusivity. METHODS: a 
group of frequently prescribed drugs with patent expiry between the years of 2001 and 
2008 are investigated and the sales and unit data in the statutory health insurance system 
are analyzed for a period one year before and two year post patent expiry. RESULTS: 
The data show for the group with reference price and no tender contract (RP+/TC-) and 
with no reference price but tender contracts (RP-/TC+) similar level for the sales but 
signiﬁ cantly higher volume data for the ﬁ rst group. In the ﬁ rst year post patent expiry 
there seams to be a signiﬁ cant drop of sales and volume 9–12 month post patent expiry—
a period, when usually the reference price is set. The ﬁ gures for the groups with tender 
contracts (TC+) show a more steadily decline post patent expiry. The group RP+/TC+ 
is in terms of cost containment (sales decline) the most prominent one. If no regulation 
takes place, sales and volume increases even post patent expiry. CONCLUSIONS: Refer-
ence pricing and tender contracts are two cost containment measures, which are equally 
effective if applied alone, and which have additional impact, when applied together.
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OBJECTIVES: Considering the pharmaceutical expenditure trend and the current eco-
nomic and social context in Portugal, this study aims to: 1) analyze the national and 
international policy environments in Europe and US, concerning INN prescription and 
generic substitution, and 2) calculate the effect of generic substitution in Portugal, in terms 
of savings for the NHS and patients. METHODS: We conducted an international legisla-
tion review and generics market data. We estimated annual savings under the assumption 
of gradual increase in generics market share, and considering the difference between 
branded and generic medicines prices for each group of the Reference Price System (RPS). 
The database includes sales from Portuguese community pharmacies. RESULTS: The INN 
prescription is allowed in 20 countries of all 27 European countries and in all 50 US states. 
The generic substitution by pharmacists is allowed in 21 European countries (mandatory 
in 8) and in all US states (mandatory in 14). Despite the high increase from 2002, generics 
market share in Portugal is still below the European average, furthermore with a slowdown 
in its growth since 2005. The doctors prescribed 39.1% of drugs by brand name with no 
permission for substitution in 2009. The simulations generated savings of c120.4 million 
(50.8 for the NHS and c69.6 million for patients), less 11.1% of the medicines expenditure 
covered by the RPS. CONCLUSIONS: The market shares observed seem to reﬂ ect the 
different legislative frameworks. In Portugal, despite the growing share of generics, there 
is still a large potential market with signiﬁ cant opportunities of additional savings for the 
health system and patients, and may contribute to a higher pharmaceuticals accessibility 
as well to maximize therapeutic adherence.
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OBJECTIVES: The Stability and Growth Pact approved by the Portuguese Govern-
ment in 2010 limits the annual growth of public expenditure in 1% for drugs reim-
bursed in outpatient sector. Considering the 10.4% increased in pharmaceutical 
expenditure from the National Health Service (NHS) in the ﬁ rst 4 months of 2010, 
this study aims to identify the main factors of expenditure growth and implications 
of legislative modiﬁ cations in Portugal. METHODS: We have considered the policy 
changes concerning pricing and reimbursement and analyzed the database that 
includes sales from Portuguese community pharmacies and drugs prescription data. 
The statistical analysis of monthly data by product was performed with Statistical 
Analysis System (SAS), version 8.2. RESULTS: The new legislation approved in June 
2009, that establishes the generics reimbursement at 100% for pensioners whose 
income is below the national minimum wage was responsible for more c20.4 million 
of NHS spending in 2010. The special reimbursement regimes had also contributed 
positively for this trend: for example, the reimbursement rate raise for some anti-
asthmatics (from 37% to 69%) was responsible for c5.1 million (10.3%) of NHS 
expenditure increase. Nevertheless c10.7 million (21.5% of NHS expenditure growth) 
are explained by the top 10 branded drugs recently reimbursed (5 oral antidiabetics 
and 1 insulin). The reform in reimbursement system approved for July 2010 also 
predicts major changes in the expenditures trends. CONCLUSIONS: The legal frame-
work has a high impact in pharmaceuticals expenditures trends, and consequently in 
public ﬁ nancial burden and patient co-payments. The different policy measures 
adopted should be assessed on a periodic basis in order to monitor the market dynam-
ics and to identify the strategies that support the sustainable expenditure growth.
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IN EUROPE
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OBJECTIVES: Due to the dynamic increase of pharmaceutical expenditure in the last 
decade different cost-containment method has been introduced by the European public 
insurance companies. The cost-effective drug reimbursement system might inﬂ uence 
the price level either in a direct or an indirect way, so the pricing strategy should be 
based on demand drivers and on factors of the regulatory environment as well. The 
goal of this analysis was to identify the effect the certain reimbursement solutions and 
local market characteristic on average price level of the predeﬁ ned submarket. 
METHODS: Before the statistical analysis we have built a comprehensive, standard-
ized and continuously updated international drug database based on ofﬁ cial sources 
which supported the analysis trough getting wider access to data’s. Because of the 
expected domestic introduce of international reference price system, we handled it 
with an extra attention among the explanatory variables. RESULTS: The variance of 
international pharmaceutical price level by the examined submarket found to be 
remarkable which can be explained by the difference product supply and the different 
apply of cost-containment methods of price regulation. CONCLUSIONS: The most 
effective way to curb the increased expenditure by the patient and the public insurance 
companies seems to be international reference price system; however the effect of this 
method differs across the countries.
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A PROPOSAL FOR CLASSIFICATION OF PUBLIC FUNDING 
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OBJECTIVES: Increasingly difﬁ cult situation of health care systems forces decision 
makers to limit access to publicly funded drugs compared to registration conditions. 
To keep the transparency, the decisions to deny health intervention to some group of 
patients have to be publicly justiﬁ ed—simple intuition is not enough. The objective is 
to present initial classiﬁ cation and details of methods to generate public funding 
restrictions. METHODS: A pool of public funding decisions has been identiﬁ ed 
through search of internet websites of the institutions that recommend or actually 
make public funding decisions. The speciﬁ c conditions restricting the access were 
identiﬁ ed, grouped and further analyzed together with their justiﬁ cation if available. 
RESULTS: All restrictions generally aim to optimize the performance of the decision 
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in regard to public funding criteria. The following main types of restrictions were 
identiﬁ ed either because of the target public funding parameter affected or because of 
the reasoning: a) “because of lack of evidence”; b) “because it is the only effective 
treatment” (rule of rescue); c) “to improve efﬁ cacy”; d) “to improve efﬁ cacy-safety 
relation”; e) “to improve effectiveness”; f) “to improve cost-effectiveness”; and g) “to 
limit budget impact”. CONCLUSIONS: The limiting conditions should be perceived 
as tools to enable positive public funding decision when the current scope of ﬁ nancing 
is just behind the hypothetical threshold. Exploring and further analyzing methods 
and aspects concerning generating public funding restrictions is important for: 1) 
decision makers, so they be more aware of the consequences and impact of their 
decisions on the people/patients they serve, and could make more transparent deci-
sions; 2) HTA analysts, to focus their interest on the subsequent use of HTAs to help 
decision makers identify all potential options to rationally limit funding; 3) Market 
Access managers, so they used the identiﬁ ed mechanisms and methods to better foresee 
the public funding decisions concerning their drugs.
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ASSESSING PUBLIC ACCOUNTABILITY OF KOREAN DRUG 
REIMBURSEMENT DECISION PROCESS
Cho E, Kang M
Yonsei University, Seoul, South Korea
OBJECTIVES: Since economic evaluation has been enforced to be considered for new 
drug reimbursement decisions in 2007, the structure and constituents of decision body, 
“Drug Reimbursement Evaluation Committee”, as well as the pharmacoeconomics 
report guideline promulgated by Health Insurance Review Assessment have been 
modiﬁ ed in Korea. These changes reﬂ ect deﬁ ciency in systematic adoption of economic 
evaluation and discontent among stakeholders. Recently, the fair and reasonable 
process and criteria have been highly emphasized at every level of policy administra-
tion in developed countries with concerns of increasing public demands for sustainable 
public practices and political acceptance of the importance of public accountability. 
Now, imminent practical task is how to connect the conceptual framework and fea-
sible practice for publicly accountable drug reimbursement decisions. METHODS: 
Using theoretical structure of public accountability published in the European Gover-
nance Paper, we analyzed qualiﬁ cations of drug reimbursement policy as ‘account-
ability’ and appraised the public accountability. We also performed interviews with 
ten key stakeholders from democratic, constitutional and learning perspectives. And 
then, recent reimbursement decision papers on two new drugs were analyzed to 
examine concrete shape of the accountability forums. RESULTS: Following scope of 
improvement would be suggested: (1) Clear and reasonable standards for coverage 
decision; (2) relevance of the standards to population’s health needs and health equity 
impacts; (3) disclosure of data used for decision, procedure and results to public; and 
(4) the procurement of due process of challenging decisions. CONCLUSIONS: Given 
value pluralism in democratic liberalism, it is matter of course that formal or proce-
dural justice is given prominence. Conclusively, an explicit discussion for formal cri-
teria and procedure is the essential component of the ongoing policy process. 
Accountable drug policy administration is impossible without accountable policy 
process which is impossible without transparent criteria for all decision stages.
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BACKGROUND: In Western jurisdictions, coverage with evidence development (CED) 
is seen as a promising scheme for linking coverage decisions on innovative health tech-
nologies with the generation of additional evidence. Nonetheless, the implementation of 
such CED schemes is not guaranteed to be successful, with issues arising around both 
evidence generation and (dis)continued coverage of technologies. OBJECTIVES: This 
qualitative study aims to explore the practical experiences with CED schemes for tech-
nology coverage. METHODS: Semi-structured interviews were conducted with key 
stakeholders involved in the decision making process about reimbursement of health 
technologies in Australia, Belgium, Ontario (Canada), France, Germany, Galicia (Spain), 
Sweden, UK and USA. The questionnaire for the interview was developed on the basis 
of comprehensive literature review and expert opinion, addressing issues related to the 
aim of CED, initial assessment/appraisal, evidence development, re-assessment/re-
appraisal and coverage for technologies. RESULTS: CED schemes vary widely in the 
evidence generation, time frame, the regulation and funding of research, and the involve-
ment of stakeholders in the CED process. This variation is caused by the structure and 
ﬁ nancing of health services delivery, the aim of CED, and the type of health technology. 
The CED process is often non-transparent, particularly relating to the selection of 
technologies and the re-assessment/re-appraisal for coverage (dis)continuation. (Dis)
continued coverage of technologies is often primarily driven by the pressures from 
patients, health professional and health institutions to provide access to innovative 
technologies or public opinion. CONCLUSIONS: The successful implementation of 
CED schemes requires: a) a transparent (analytic) framework for the selection of health 
technologies and the generation of additional evidence; b) a clear legal authority to regu-
late evidence generation, time frame and research budget; c) a structural involvement of 
stakeholders in the process of CED; and d) a priori clear end points for the re-assessment/
re-appraisal and technology coverage. 
HEALTH CARE USE & POLICY STUDIES – Health Care Research & 
Education
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THE ROLE OF VALUE OF INFORMATION ANALYSIS IN HEALTH CARE 
RESEARCH PRIORITY SETTING: A THEORETICAL CASE STUDY
Corro Ramos I, Rutten-van Mölken MP, Al MJ
Erasmus University, Rotterdam, The Netherlands
BACKGROUND: The Dutch reimbursement procedure for expensive hospital drugs 
requires the submission of a baseline cost-effectiveness analysis together with a 
research plan for the period of temporary reimbursement in order to estimate the 
real-life cost-effectiveness after 4 years. In this situation, a Value-of-Information (VOI) 
analysis might identify the critical parameters that need to be studied in such outcome 
study. OBJECTIVES: To identify when a VOI analysis alongside sensitivity analyses 
is warranted, and when such VOI analysis will not impact the decision making process. 
METHODS: We used a hypothetical Markov model with three groups of parameters: 
costs, utilities and transition probabilities. We studied different conﬁ gurations of input 
parameters, forcing the outcomes into different directions on the CE-plane. For each 
input conﬁ guration we performed a multivariate sensitivity analysis (MSA) and a 
probabilistic sensitivity analysis (PSA). In the MSA, sensitivity was measured as per-
centage change from baseline INMB. Additionally, we analyzed the expected value of 
perfect information (EVPI) and the expected value of partial perfect information 
(EVPPI). Analyses were done for a range of threshold ICERs. RESULTS: For each 
situation it was possible to predict the shape (but not the absolute value) of the EVPI 
curve based on the PSA ﬁ ndings. When the PSA plot covered both northern quadrants, 
MSA and EVPPI came to the same ranking of the groups of parameters. When the 
outcomes were in the northeast quadrant the ranking differed: MSA indicated costs 
as most important parameters, for EVPPI this was utilities. When outcomes where in 
the southwest quadrant, costs were most important in MSA and EVPPI. For both 
other quadrants, MSA and EVPPI were close to zero for all groups. CONCLUSIONS: 
Whether MSA and EVPPI come to a different priority setting for future research 
depends both on the threshold ICER and on the location of results on the 
CE-plane.
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OBJECTIVES: To identify stakeholder perceptions of sponsored clinical trials in a 
publically funded New Zealand hospital, and then to identify the similarities and 
differences in perceptions across these stakeholder groups. The stakeholders are: 1) 
participants involved in clinical trials; 2) management and the multidisciplinary team; 
3) the larger South Auckland community; 4) government and decision makers; and 5) 
the pharmaceutical industry. METHODS: We use purposive sampling to select repre-
sentatives of the stakeholder groups, which provides 109 respondents. We gather data 
using focus groups, in-depth interviews, telephone interviews and surveys. RESULTS: 
Many of the respondents represent more than one stakeholder group. While there is 
consensus across the stakeholders on some costs and beneﬁ ts such as developing safe 
medicines and collecting useful data there are marked differences in perceptions in 
other areas, such as those indicated below. Most stakeholders perceive the risk of 
adverse reactions as the greatest cost to trial participants but the participants them-
selves do not regard this as signiﬁ cant. Pharmaceutical representatives, management 
and the multidisciplinary team feel that gaining access to new medicines motivates 
people to participate in a trial. Trial participants feel that the support is more impor-
tant to them than the medication. Most researchers and staff believe trial involvement 
increases their job satisfaction, motivation, knowledge and skills while a few have 
concerns that sponsor control leads to the loss of their ﬂ exibility and independence 
Generally there is a perception that New Zealand based clinical trials assist in the 
process of obtaining registration and subsidization of new drugs in New Zealand. 
However, this perception may be erroneous as location of trials is apparently not 
considered in the drug registration process. CONCLUSIONS: We ﬁ nd that most 
stakeholders are satisﬁ ed with the conduct of clinical trials in New Zealand and they 
believe the beneﬁ ts outweigh the costs.
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PHYSICIANS AND MOTIVATION TO PARTICIPATE: FRENCH 
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OBJECTIVES: Recent development of Health Technology Assessment worldwide 
increased requirement for real world data (e,g, risk management plans, drugs utiliza-
tion). Primary non-interventional research (NIR) involving physicians able to enrol 
patients is a means to generate such data. One key challenge of NIRs is the capacity 
to reﬂ ect real life conditions by providing unbiased estimations of physicians’ behav-
iours and patients outcomes in large representative samples. Participation of physi-
cians is often an issue when conducting NIRs. Lack of understanding of scientiﬁ c value 
of NIRs, compared to clinical trials, is often assumed to be the major reason for 
reluctance to participate. Our objective was to better understand perception of, moti-
vation to participate in and expectation from participation in NIRs by physicians. 
